Fructose-1,6-bisphosphatase opposes renal carcinoma progression
about
Novel drugs that target the metabolic reprogramming in renal cell cancerLeishmania carbon metabolism in the macrophage phagolysosome- feast or famine?Cancer stem cells: targeting the roots of cancer, seeds of metastasis, and sources of therapy resistanceUndercover: gene control by metabolites and metabolic enzymesThe ever-expanding role of HIF in tumour and stromal biologyMetabolic pathways promoting cancer cell survival and growthAnalysis and interpretation of transcriptomic data obtained from extended Warburg effect genes in patients with clear cell renal cell carcinoma.Ribonucleotide Reductase Requires Subunit Switching in Hypoxia to Maintain DNA ReplicationFBP1 expression is associated with basal-like breast carcinomaAssociations among Metabolism, Circadian Rhythm and Age-Associated DiseasesIntratumor Heterogeneity in Primary Kidney Cancer Revealed by Metabolic Profiling of Multiple Spatially Separated Samples within Tumors.Elucidation of new condition-dependent roles for fructose-1,6-bisphosphatase linked to cofactor balances.Reprogramming glucose metabolism in cancer: can it be exploited for cancer therapy?Flux balance analysis predicts essential genes in clear cell renal cell carcinoma metabolism.MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolismMeta-Analysis of Tumor Stem-Like Breast Cancer Cells Using Gene Set and Network Analysis.PBRM1 Regulates the Expression of Genes Involved in Metabolism and Cell Adhesion in Renal Clear Cell CarcinomaDownregulation of FBP1 Promotes Tumor Metastasis and Indicates Poor Prognosis in Gastric Cancer via Regulating Epithelial-Mesenchymal Transition.NPM1 activates metabolic changes by inhibiting FBP1 while promoting the tumorigenicity of pancreatic cancer cells.EGFR Signaling Enhances Aerobic Glycolysis in Triple-Negative Breast Cancer Cells to Promote Tumor Growth and Immune Escape.An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma.Association between FBP1 and hypoxia-related gene expression in clear cell renal cell carcinomaAlternate Metabolic Programs Define Regional Variation of Relevant Biological Features in Renal Cell Carcinoma Progression.Methylomes of renal cell lines and tumors or metastases differ significantly with impact on pharmacogenesInsights into the Genetic Basis of the Renal Cell Carcinomas from The Cancer Genome Atlas.Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer.The platelet isoform of phosphofructokinase contributes to metabolic reprogramming and maintains cell proliferation in clear cell renal cell carcinoma.Meta-analysis of gene expression studies in endometrial cancer identifies gene expression profiles associated with aggressive disease and patient outcome.Downregulation of HSP60 disrupts mitochondrial proteostasis to promote tumorigenesis and progression in clear cell renal cell carcinomaPersonalized Prediction of Proliferation Rates and Metabolic Liabilities in Cancer Biopsies.Snail reprograms glucose metabolism by repressing phosphofructokinase PFKP allowing cancer cell survival under metabolic stress.Recurrent patterns of DNA copy number alterations in tumors reflect metabolic selection pressures.Nur77 suppresses hepatocellular carcinoma via switching glucose metabolism toward gluconeogenesis through attenuating phosphoenolpyruvate carboxykinase sumoylation.Inhibiting histone deacetylases suppresses glucose metabolism and hepatocellular carcinoma growth by restoring FBP1 expression.Targeting renal cell carcinoma with a HIF-2 antagonist.Induction of LIFR confers a dormancy phenotype in breast cancer cells disseminated to the bone marrow.Kidney cancer in 2014: Key advances promise progress for kidney cancer patients.Loss of fructose-1,6-bisphosphatase induces glycolysis and promotes apoptosis resistance of cancer stem-like cells: an important role in hexavalent chromium-induced carcinogenesis.Glutamine fuels proliferation but not migration of endothelial cells.Pyruvate kinase M2 activation may protect against the progression of diabetic glomerular pathology and mitochondrial dysfunction.
P2860
Q26740187-511C2727-1840-4475-B1B9-6ECBD384AEF0Q26776497-4D23B92D-CAE8-498A-A7F2-F58703D6098AQ26829987-1C050397-AB4C-4196-932B-4FF9DD856731Q28072281-14A6FE97-BBCE-47DF-82C8-EC37095F0098Q28079015-0286FB92-E909-4EA4-B969-F83EE4725569Q28086940-B1B82DB1-E2B3-411E-BDC1-767CF3B05BADQ30928926-C02C9858-255A-4E84-8631-D21BB9DD586CQ33603402-4A47ECAA-E816-4502-827E-7829E2779A09Q33686009-01D139C0-3A26-4531-AC3A-76776F70AC48Q33714257-0F8F9C9A-AA50-418F-ABB0-6797E704EA25Q33715755-18E0D73B-E10F-4AB9-B690-85E3A4AEC48DQ33728044-249369DB-BFB3-45F7-8EC5-D7FE1076601EQ33917658-E0E1213A-237B-4700-8FC9-63D481213000Q34044149-7C33DFF4-2950-4838-9263-71CD8C3A3385Q35669189-8F086D63-7B70-4CC7-A5D1-5EAB99B3596EQ35921899-DC0CFE4E-23CB-4BBE-AE36-8F3CF5CA362AQ35995926-E19C3BFD-501D-4C79-A700-DD1C054A7902Q36225499-2ADA19DF-CC99-4B0F-95D2-A0266254E931Q36356360-22C213B0-7FA9-4A16-8733-C7727099383CQ36642685-E9DE2021-20EC-4D34-AFD2-20E906C652A4Q36732789-0B8BD9F1-DD0C-4FCD-BB6F-FE4BA6D99F84Q36954700-8CD96231-ACA5-4BA7-BCEC-B7E9AB0DDEEEQ37014111-716C26DF-D62A-4ED4-B454-D6A91647B8F8Q37110909-FE888581-2F8C-40EB-8032-4634057731CDQ37114357-08C7C841-F320-44B7-A430-A6D195E3D6A9Q37234734-BAE00190-2483-4FC4-91AA-E1BD3A106339Q37317189-8CD3C12F-00E3-4629-85AB-2E17EC525907Q37405608-F8E86680-3A2A-4116-974C-B76E8EB3FEDAQ37437672-3D0F09B7-1844-4809-ABC4-E97EE533B0FFQ37532946-6BF940C1-D948-4441-8CA6-0A2FB7A0D8D8Q37642617-5568ACBF-88DF-47F9-87D4-85B27EAEAC74Q37668791-0B7BC08B-5B6E-44C2-9522-31F56A964A41Q37676708-2E3C2FCA-336B-4B1B-94D8-BB35BA5C14B4Q37682212-1DF53456-BE93-4B62-8397-7E62DE61B3BDQ37684974-576682B0-BC77-4E8B-B2F1-D339F5AC6D35Q37710308-CB3CBC99-4CA0-4568-BDA0-3C9A623DB97DQ38323542-D07CC07D-4033-46F3-B359-74080C7D1CACQ38700019-1931B05B-CA0D-424C-8924-4F535496AAB9Q38703910-B69BAD15-499A-496D-AE61-0B3ED49DE941Q38706335-8D8A6D88-E08B-4E7F-8361-2822361D3039
P2860
Fructose-1,6-bisphosphatase opposes renal carcinoma progression
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Fructose-1,6-bisphosphatase opposes renal carcinoma progression
@ast
Fructose-1,6-bisphosphatase opposes renal carcinoma progression
@en
Fructose-1,6-bisphosphatase opposes renal carcinoma progression
@nl
type
label
Fructose-1,6-bisphosphatase opposes renal carcinoma progression
@ast
Fructose-1,6-bisphosphatase opposes renal carcinoma progression
@en
Fructose-1,6-bisphosphatase opposes renal carcinoma progression
@nl
prefLabel
Fructose-1,6-bisphosphatase opposes renal carcinoma progression
@ast
Fructose-1,6-bisphosphatase opposes renal carcinoma progression
@en
Fructose-1,6-bisphosphatase opposes renal carcinoma progression
@nl
P2093
P2860
P921
P356
P1433
P1476
Fructose-1,6-bisphosphatase opposes renal carcinoma progression
@en
P2093
Anthony Mancuso
Brian Keith
Itzhak Nissim
Joshua D Ochocki
Lijoy K Mathew
M Celeste Simon
Terence P F Gade
Zandra E Walton
P2860
P2888
P304
P356
10.1038/NATURE13557
P407
P577
2014-07-20T00:00:00Z
P5875
P6179
1024513101